Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
[en] BACKGROUND: The multicentre, randomised Benestent-II study investigated a strategy of implantation of a heparin-coated Palmar-Schatz stent plus antiplatelet drugs compared with the use of balloon angioplasty in selected patients with stable or stabilised unstable angina, with one or more de-novo lesions, less than 18 mm long, in vessels of diameter 3 mm or more. METHODS: 827 patients were randomly assigned stent implantation (414 patients) or standard balloon angioplasty (413 patients). The primary clinical endpoint was event-free survival at 6 months, including death, myocardial infarction, and the need for revascularisation. The secondary endpoints were the restenosis rate at 6 months and the cost-effectiveness at 12 months. There was also one-to-one subrandomisation to either clinical and angiographic follow-up or clinical follow-up alone. Analyses were by intention to treat. FINDINGS: Four patients (one stent group, three angioplasty group) were excluded from analysis since no lesion was found. At 6 months, a primary clinical endpoint had occurred in 53 (12.8%) of 413 patients in the stent group and 79 (19.3%) of 410 in the angioplasty group (p=0.013). This significant difference in clinical outcome was maintained at 12 months. In the subgroup assigned angiographic follow-up, the mean minimum lumen diameter was greater in the stent group than in the balloon-angioplasty group, (1.89 [SD 0.65] vs 1.66 [0.57] mm, p=0.0002), which corresponds to restenosis rates (diameter stenosis > or =50%) of 16% and 31% (p=0.0008). In the group assigned clinical follow-up alone, event-free survival rate at 12 months was higher in the stent group than the balloon-angioplasty group (0.89 vs 0.79, p=0.004) at a cost of an additional 2085 Dutch guilders (US$1020) per patient. INTERPRETATION: Over 12-month follow-up, a strategy of elective stenting with heparin-coated stents is more effective but also more costly than balloon angioplasty.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Serruys, P. W.
van Hout, B.
Bonnier, H.
Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
Serruys PW, De Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95.
Fischman D, Leon M, Baim D, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
Topol E. Caveats about elective coronary stenting. N Engl J Med 1994; 331: 539-41.
Serruys PW, Emanuelsson H, Van Der Giessen W, et al. Heparincoated Palmaz-Schatz stents in human coronary arteries: early outcome of the Benestent-II pilot study. Circulation 1996; 93: 412-22.
Gawaz M, Neumann FJ, Ott I, May A, Schömig A. Platelet activation and coronary stent implantation: effect of antithrombotic therapy. Circulation 1996; 94: 279-85.
Serruys PW, di Mario C. Who was thrombogenic: the stent or the doctor? Circulation 1995; 91: 1891-93.
Van Hout B, Van Der Woude T, De Jaegere P, et al. Cost effectiveness of stent implantation versus PTCA: the Benestent experience. Semin Intervent Cardiol 1996; 1: 263-68.
Van Hout B, Al M, Gordon G, Rutten F. Cost effects and C/E-ratios alongside a clinical trial. Health Economics 1996; 3: 309-19.
Braunwald E. Unstable angina: a classification. Circulation 1989; 80: 410-14.
Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 1991; 324: 13-17.
Blackburn H, Keys A, Simon son E, Rautaharju P, Punsar S. The electrocardiogram in population studies: a classification system. Circulation 1960; 21: 1160-75.
Escaned J, Folley DP, Haase J, et al. Quantitative angiography during coronary angioplasty with a single angiographic view: a comparison of automated edge detection and videodensitrometric techniques. Am Heart J 1993; 126: 1326-33.
Van Hout BA, Bowman L, Zelinger DJ, Simoons ML. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Eur Heart J 1998; 19 (suppl D): D59-66.
Brand M van den, Halem C van, Brink van den, et al. Comparison of costs of percutaneous transluminal coronary angioplasty and coronary bypass surgery for patients with angina pectoris. Eur Heart J 1990; 11: 765-71.
Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985; 41: 55-68.
Fiel1er EC. Some probability interval estimates. J Roy Statist Soc series B 1954; 16: 175-83.
Black WC. The cost-effectiveness plane: a graphic representation of cost-effectiveness. Medical Decision Making 1990; 1: 212.
Ellis SG, Roubin GS, King SBIII, Douglas JS Jr, Cos WR. Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty. Am J Cardiol 1989; 63: 30-34.
The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase 1 findings. N Engl J Med 1985; 312: 932-36.
Herrman JP, Azar AJ, Umans AWM, Boersma E, Es van GA, Serruys PW. Inter-and intra-observer variability in the qualitative categorization of coronary angiograms. Int J Cardiac Imaging 1996; 12: 21-30.
Dorros G, Cowley MJ, Simpson J, et al. Percutaneous transluminal coronary angioplasty: report of complications from the National Heart, Lung and Blood Institute PTCA Registry. Circulation 1983; 67: 723-30.
Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-89.
Serruys PW, Grines CL, Stone GW, et al. Stenting in acute myocardial infarction using a heparin-coated stent: a pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting. Int J Carciovascular Intervent (in press).
Chronos NAF, Robinson KA, King III SB, et al. Heparin coated Palmaz-Schatz stents are highly thrombo-resistant: a baboon A-V shunt study. Am J Coll Cardiol 1996; 27 (suppl A): 904 (abstr).
Hard hammer PA, Van Beusekom H , Emanuelsson H V, et al. Reduction of thrombotic events using heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996; 93: 423-30.
Palmar-Schatz balloon-expandable stent and delivery system: PM A 900043 panel package: circulatory system devices panel: May 3, 1994. Division on cardiovascular, respiratory and neurological devices: US Food and Drug Administration.
Bertrant ME, Allain H, Lablanche J. Results of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty (PTCA): the TACT study. Circulation 1990; 82 (suppl III): 190 (abstr).
The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
Ellis SG, Serruys PW, Popma JJ, et al. Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents?: the final eraser results. Circulation 1997; 96: 1-87.
Erbel R, Haude M, Höpp H W, et al, on behalf of the REST Study Group. Randomized trial comparing stenting and balloon angioplasty for treatment of restenosis after balloon angioplasty. Am J Coll Cardiol 1996; 27 (suppl A): 139 (abstr).
Rupprecht H-J, Espinola-Klein C, Erber R, Nafe B, Brennecke R, Dietz U, Meyer J. Impact of routine angiographic follow-up after angioplasty. Am Heart J (in press).
